- 88
- 164 177
Imugene Limited
Australia
Приєднався 9 лис 2018
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors.
MISSION
• Our mission is to develop transformative cancer medicines to improve patients’ lives and to establish value and trust with our stakeholders.
VALUES
• Compassion: we feel empathy and kindness towards our patients and their families. We put patients first.
• Relationships: we value positive, respectful and collaborative relationships
• Integrity: we observe and adhere to good scientific practice and standards
• Trust: we will be good stewards of our investors capital
• Innovation: we strive to be bold and brave in our thinking
• Sustainability: we strive to develop safe and ethical products
• Collaboration: the diverse voices of our people are our greatest asset
MISSION
• Our mission is to develop transformative cancer medicines to improve patients’ lives and to establish value and trust with our stakeholders.
VALUES
• Compassion: we feel empathy and kindness towards our patients and their families. We put patients first.
• Relationships: we value positive, respectful and collaborative relationships
• Integrity: we observe and adhere to good scientific practice and standards
• Trust: we will be good stewards of our investors capital
• Innovation: we strive to be bold and brave in our thinking
• Sustainability: we strive to develop safe and ethical products
• Collaboration: the diverse voices of our people are our greatest asset
Meet Garrett Gincley, Vice President of Cell Therapy, External Manufacturing, and Imugene Quality.
Meet Garrett Gincley, Vice President of Cell Therapy, External Manufacturing, and Imugene Quality. In this video, Garrett shares his passion for advancing azer-cel, an innovative off-the-shelf CAR T therapy developed from healthy donor T cells. With over five years of experience working on azer-cel, he expresses his excitement about its potential to be a lifesaving treatment for cancer patients worldwide. Join him as he discusses the exciting progress Imugene is making in the fight against cancer.
Переглядів: 340
Відео
Meet Tilanthi Jayawardena, Imugene’s Translational Sciences Lead for azer-cel.
Переглядів 20028 днів тому
Meet Tilanthi Jayawardena, Imugene’s Translational Sciences Lead for azer-cel. In this video, Tilanthi shares her journey in cell therapy, from her early work in 2019 to joining Imugene in 2023. She discusses the exciting progress of azer-cel in the clinic and its potential to make a significant impact for patients in need.
Investor webinar: Azer-cel trial update, September 2024
Переглядів 990Місяць тому
Watch the replay of Imugene's investor webinar held on 4 September 2024. During the webinar, Imugene's Managing Director and CEO Leslie Chong, along with Chief Medical Officer Dr. Paul Woodard, discuss the latest data from the azer-cel Phase 1b clinical trial in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This update follows the announcement made on 2 September 2024, highlighting...
Imugene reports promising results in Phase 1b trial for azer-cel in DLBCL
Переглядів 547Місяць тому
Imugene Ltd (ASX: IMU) chief operating officer Brad Glover and CEO Leslie Chong sit down with Proactive’s Tylah Tully to discuss positive results from its Phase 1b clinical trial of azer-cel (azercabtagene zapreleucel), an allogeneic off-the-shelf CD19 CAR T therapy, in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). This trial addresses a significant unmet need as all ...
CEO Leslie Chong And COO Dr Bradley Glover Speak With JustStocks Video
Переглядів 834Місяць тому
CEO Leslie Chong And COO Dr Bradley Glover Speak With JustStocks Video; Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)
CAR T Explained
Переглядів 7052 місяці тому
What do frozen samurai warriors and magic goggles have to do with treating cancer? Join Imugene on a journey into the future of cancer therapies, and learn how new genome editing technology-is used to make off-the-shelf, donor-derived CAR T cell therapies with the potential to change the way the world battles cancer.
Developing Cancer Cures through the ASX | Going Public w Leslie Chong & Paul Hopper
Переглядів 2,2 тис.2 місяці тому
Imugene Ltd (ASX: IMU) is excited to share the 12th episode of 'Going Public' on Australia's leading investing platform. This monthly series offers unique access to the entrepreneurs, founders, and executives who have taken their businesses public. In this episode, we delve into the remarkable journey of Imugene, a clinical-stage immuno-oncology company revolutionising cancer treatment with cut...
Leslie Chong & Dr Yuman Fong speak to JustStocks on latest With onCARlytics & MAST Clinical Trials
Переглядів 1,4 тис.3 місяці тому
Imugene Limited (ASX:IMU) CEO Leslie Chong And CF33 inventor Dr Yuman Fong provide an update to JustStocks Video on the latest with the company’s Phase 1 bile tract cancer study and Phase 1 onCARlytics trial.
Imugene begins VAXINIA trial for bile tract cancer
Переглядів 1,4 тис.3 місяці тому
Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong and strategic advisor Dr Yuman Fong sit down with Proactive’s Jonathan Jackson to discuss Professor Fong’s expertise and the latest company developments. Dr Fong is a world-renowned cancer researcher, physician and surgeon whose clinical work has focused on OV for more than 30 years. He is the inventor of OV CF33. Imugene h...
Imugene (ASX:IMU) doses first patient in IV arm of Phase 1 onCARlytics trial targeting solid cancers
Переглядів 6463 місяці тому
Our MD & CEO, Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss our recent milestone: dosing the first patient in the intravenous (IV) infusion combination arm of our Phase 1 onCARlytics trial. This patient, diagnosed with cholangiocarcinoma, received treatment at City of Hope in California. Our OASIS trial is the first to combine a CD19-expressing oncolytic virus with a CD19-...
Imugene (ASX:IMU) | JMM & éthica Capital Innovation Interview \\ May 2024
Переглядів 9845 місяців тому
CEO & Managing Director Leslie Chong interview with JMM and éthica Capital 🔗 Stay Connected: www.imugene.com Follow us on Twitter: @TeamImugene Connect with us on LinkedIn: www.linkedin.com/company/imugene/ Explore more on our website: www.imugene.com #Imugene #CancerResearch #Biotech #Immunotherapy #Oncology #AusBiz
Imugene (ASX:IMU) | JMM & éthica Capital Innovation & Investment Insights | May 2024
Переглядів 2,3 тис.5 місяців тому
Imugene's CEO & Managing Director Leslie Chong recently delivered a dynamic 'stand-up and pitch' presentation to investors in Sydney. In her talk, she briefly recounted her journey to leading Imugene's team, which collectively boasts over 150 years of experience. She shared updates on the Phase 1B Study, the sale of our manufacturing facility in North Carolina, and our oncarlytic Phase One stud...
Investor webinar - Imugene Limited (ASX:IMU) & Kincell Bio Strategic Partnership Investor Webinar
Переглядів 1,1 тис.5 місяців тому
Join us for a comprehensive discussion on the newly announced strategic partnership between Imugene Limited (ASX: IMU) and Kincell Bio, LLC. This investor webinar, originally held on 18 April 2024, features insights from Imugene's Managing Director and CEO, Leslie Chong, COO Dr. Bradley Glover, and Kincell Bio's CEO, Dr. Bruce Thompson. Hosted by Imugene's U.S. Head of Investor Relations, Heath...
MD & CEO Leslie Chong Discusses Bile Tract Cancer Study Expansion & Strategic Partnership
Переглядів 6906 місяців тому
Join Leslie Chong, Managing Director & CEO of Imugene Ltd (ASX:IMU), as she provides an insightful update on the latest developments at Imugene. In this video, Dr. Chong discusses the expansion of our clinical study targeting Bile Tract Cancer, a crucial part of our VAXINIA MAST program. The expansion trial aims to enrol 10 patients, marking a significant step forward in our research efforts. A...
Leslie Chong Discusses Imugene's Strategic Partnership with Kincell Bio | AusBiz Interview
Переглядів 8746 місяців тому
Join Imugene’s Managing Director & CEO, Leslie Chong, in an insightful interview on AusBiz, where she discusses our groundbreaking strategic partnership with Kincell Bio. This partnership is set to enhance our efforts in pioneering new cancer treatments through advanced immuno-oncology therapies. In this interview, Leslie outlines the implications of our cutting-edge CAR T and oncolytic virothe...
Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
Переглядів 7456 місяців тому
Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
Imugene opens enrolment for Bile Tract Cancer expansion study
Переглядів 6286 місяців тому
Imugene opens enrolment for Bile Tract Cancer expansion study
Imugene Limited: ASX Small and Mid Cap Conference March 2024
Переглядів 8186 місяців тому
Imugene Limited: ASX Small and Mid Cap Conference March 2024
Imugene with Proactive at ASX Small and Mid Cap Conference
Переглядів 6816 місяців тому
Imugene with Proactive at ASX Small and Mid Cap Conference
Imugene (ASX:IMU) Presentation, NWR Virtual Healthcare Conference
Переглядів 7286 місяців тому
Imugene (ASX:IMU) Presentation, NWR Virtual Healthcare Conference
Imugene Limited (ASX: IMU) Emergence 2024: Presentation by Leslie Chong, Managing Director and CEO
Переглядів 1,7 тис.7 місяців тому
Imugene Limited (ASX: IMU) Emergence 2024: Presentation by Leslie Chong, Managing Director and CEO
Imugene progresses onCARlytics solid tumour trial to combination arm
Переглядів 4357 місяців тому
Imugene progresses onCARlytics solid tumour trial to combination arm
Imugene Ltd MD and CEO shares with JustStocks plans for Phase 1 onCARlytics Combination Study
Переглядів 8067 місяців тому
Imugene Ltd MD and CEO shares with JustStocks plans for Phase 1 onCARlytics Combination Study
Imugene's Presentation at the Capital HQ MasterClass
Переглядів 8307 місяців тому
Imugene's Presentation at the Capital HQ MasterClass
Imugene Ltd CEO & Managing Director Leslie Chong speaks with JustStocks
Переглядів 8328 місяців тому
Imugene Ltd CEO & Managing Director Leslie Chong speaks with JustStocks
Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial
Переглядів 1 тис.8 місяців тому
Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial
7 News Australia | Australian company Imugene; saving lives using a cancer eating virus
Переглядів 6 тис.8 місяців тому
7 News Australia | Australian company Imugene; saving lives using a cancer eating virus
Imugene steps up dosage at groundbreaking VAXINIA cancer trial
Переглядів 1,1 тис.8 місяців тому
Imugene steps up dosage at groundbreaking VAXINIA cancer trial
CEO Leslie Chong interview with Proactive Investors on Phase 1 MAST Results
Переглядів 7608 місяців тому
CEO Leslie Chong interview with Proactive Investors on Phase 1 MAST Results
Imugene Limited J.P. Morgan Healthcare Conference Presentation
Переглядів 1,4 тис.9 місяців тому
Imugene Limited J.P. Morgan Healthcare Conference Presentation
God is with you
Garret, Good luck and God Speed
……
Fantastic progress IMU, well done. Looking forward to the H2 announcements.
Well done to all the Imugune team. This is hugely important work. Keep going.
God’s will for Imugene to succeed in a safe cancer vaccine
🎉😂 "off the shelf" cd19 targeting cancer therapy...with CF33 doing the infection and cd19 labelling..... patients will be diagnosed and treated the same day.....cured completely in 3 weeks by 2026....go team Imugene.....cancer on the ropes....wildfire on the cancer landscape....the biggest medical break through since penicillin.....you are making history !!!!
Congratulations to Imugene. The bottom line is sick people are getting better thanks to you.
What now?
amazing
The best description of CAR T I have seen.
Ok that was much more impressive
wow that is the best presentation to date of what IMU are developing. well done team!
Great video. Go Imugene!
Man this was kind of disappointing, I know it's under wraps most likely but I was hoping we'd hear updates. There are a not insignificant people that are looking to imugene oncolytic as their last hope. Any update on ORR or just FDA track would be a sigh of relief but I guess it won't be for another 10 years if we're lucky. Sad.
I call this one “let’s keep milking our shareholders”
I'd love to see what Imugene could do with a patient as a first treatment. Seems to me that all the trial patients are incredibly sick people with advanced cancers and compromised systems due to all the failed therapies they have already been through and we're still seeing CR's. Can only imagine how much more effective CF33 could be if it was administered straight after diagnosis
correct terminology should be "cancer is not detected" not "all the cancer is gone" 3:22 - looking forward to more data coming from this company.
Imugene is accomplishing amazing science. Patients will benefit from their work and many are waiting!
Why is it when we know that Chemotherapy and Radiation is ineffective in treating Bile Duct cancer do we have to wait for the patient to fail on this SOC before receiving treatment in the OASIS trial? It just doesn't make sense.
Truly inspiring, well done! When will we be able to see VAXINIA as a substitute of the chemotherapy? Thanks
Terrific to see Dr.Fong
You keep making all these claims it works and has essentially cured patients yet the shareholders are drowning.
Prostate cancer??
Goosebumps
Sharw price has tanked
Is it 100% successful treatment?
Too much news.. need revenue
Go Leslie and the Imugene team. 2024/2025 will be great years !
My brother is stage 4 prostate...he sudfer all his life for the violencia in Colombia .He survia a car bom were a lord drug Pablo Escobar placed in Bogotà, when he turn 40 a police shoot close to his face .cause the police officer made a huge mistake..and mistaken my brother for a thieve and now he is fighting for his life his name is Juan Mauricio Castellanos and l pray for a miracle...🔥🔥🔥🔥🔥
Thank You Imugene, your groundbreaking advances are brilliant! Congratulations!
will be interesting to see if the share price finally starts to move in the right direction, go Imugene!
This is all getting old.
I have plenty of money, you have shares, so sell them to me
Moving nicely. And we have the opportunity to enter this multi billion dollar market @ 1/100 ratio, Can't wait for next announcement. 👌
Endless promises.
Wishing Leslie and all the team well ! Keep going and rooting for you all
So if they hitting every mile stone, what does that mean for the shares will it 🚀
What the hell is this company doing lately.
Surely it should have gone up on the news, not down
How is the joke on me, numbnuts?
Lol, struggling to stay above 10 cents.
Jokes on you I paid 4 cents
I wonder if the share will hit $100 if they been getting good news most of the time.
As stage 4 patient I hope you will move quickly!
Amazing technology. I hope it all works out
The share price never seems to move much? Definatly a company to invest in though. Well done IMU
So I'm confused... cancer has taken many more lives than COVID ever will... and yet after many many years we're still no closer to FDA approved human treatments. Yet the MRNA vaccine was released in under a year, completely untested.
Cancer is not a virus, and it does not bring people to hospitals in the same place at the same time. COVID has caused hospital entrances to become saturated
Any chance this would work for fibrolamellar? flHCC is ultra rare but desperately needs better treatments.
I hope this isn't just investor hype.